Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05952960 · ClinicalTrials.gov registry record · NA

Optimizing Open Label Placebo Rationales

A NA study of Chronic Pain, sponsored by Rhode Island Hospital.

Completed
Registry status
NA
Development phase
11
Enrollment target
1
Study location

NCT05952960 is a NA study of Chronic Pain that has completed, run by Rhode Island Hospital. The registered enrollment target is 11 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05952960, a NA study of Chronic Pain, has completed, sponsored by Rhode Island Hospital.

COMPLETED
Registry status
NA
Development phase
11 participants
Enrollment target
1
Study location

Study Summary

A 3-arm randomized trial where all chronic pain patients will receive honest placebos, but the information about the placebos will differ between conditions. Outcomes are measured for 21 days and a qualitative survey will be conducted.

Conditions Studied

Interventions

  • OTHER Placebo

Study Locations (1)

Rhode Island

  • Rhode Island Hospital - Providence

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2023-07-15
Est. Completion 2023-12-31
Phase NA

Sponsor

Rhode Island Hospital

130 total trials

What the Registry Record Tells You About NCT05952960

The ClinicalTrials.gov registry entry for NCT05952960 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (99% lower). The listed sponsor is Rhode Island Hospital, which has 130 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Pain appearing as the primary indexed condition, and to 1 intervention - of which Placebo is the first listed.

NCT05952960 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.

Frequently Asked Questions

What is clinical trial NCT05952960 about?

NCT05952960 is a clinical study titled "Optimizing Open Label Placebo Rationales". A 3-arm randomized trial where all chronic pain patients will receive honest placebos, but the information about the placebos will differ between conditions. Outcomes are measured for 21 days and a qualitative survey will be conducted.

What is the current status of trial NCT05952960?

This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2023-07-15. Estimated completion is 2023-12-31.

What conditions does trial NCT05952960 study?

This clinical trial studies the following conditions: Chronic Pain.

What interventions are being tested in trial NCT05952960?

The interventions under investigation include: Placebo (OTHER).

Who is sponsoring clinical trial NCT05952960?

This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05952960 being conducted?

This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.